APA (7th ed.) Citation

SM, L., SS, K., DK, K., SH, L., CB, S., S, B., . . . BC, C. (2024). Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma. Cancer research communications, 4(7), 1748. https://doi.org/10.1158/2767-9764.CRC-24-0107

Chicago Style (17th ed.) Citation

SM, Lim, et al. "Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma." Cancer Research Communications 4, no. 7 (2024): 1748. https://doi.org/10.1158/2767-9764.CRC-24-0107.

MLA (9th ed.) Citation

SM, Lim, et al. "Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma." Cancer Research Communications, vol. 4, no. 7, 2024, p. 1748, https://doi.org/10.1158/2767-9764.CRC-24-0107.